Playback speed
10 seconds
ASCO® 2023 Insights: "KRd vs. Elotuzumab + KRd in Transplant-Eligible Pts With NDMM - Post-Induction Response and MRD Results From an Open-Label Randomized Phase 3 Study"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Stefan Knop
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Stefan Knop
104 views
June 15, 2023
Comments 0
Login to view comments.
Click here to Login